Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Utility of High Flow Nasal Cannula in CO Toxicity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03342209
Recruitment Status : Completed
First Posted : November 14, 2017
Last Update Posted : April 10, 2018
Sponsor:
Information provided by (Responsible Party):
Ibrahim Ulas Ozturan, Kocaeli University

Brief Summary:
determination of the half-life of COHb in CO-poisoned patients with high flow nasal oxygen therapy in the ED.

Condition or disease Intervention/treatment Phase
Carbon Monoxide Poisoning Environmental Exposure Device: Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy Not Applicable

Detailed Description:

Carbon monoxide (CO) poisoning is common and potentially fatal environmental emergency which requires immediate attention. It is responsible for up to 40,000 emergency department (ED) visits and 5000 to 6000 deaths per year, making it one of the leading causes of poisoning death in the United States. The management options for CO poisoning are limited to high flow oxygen by face mask or hyperbaric oxygen treatment. While half-life of carboxyhemoglobin (COHb) in a patient treating with high flow oxygen via a nonbreathing face mask is 90 minutes, it becomes 30 minutes with hyperbaric oxygen treatment (HBO).

The hypothesis of this study is using high flow nasal oxygen therapy in the CO poisoning may be more effective and safer treatment method comparing to standard oxygen therapy in the ED. Also, it may be a safe promising alternative of hyperbaric oxygen therapy.

The aim of the study is to determine the half-life of COHb in CO-poisoned patients with high flow nasal oxygen therapy in the ED.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Determination of Half-life of the Carboxyhemoglobin Level and Utility of High Flow Nasal Cannula in Carbon Monoxide Toxicity in the Emergency Department
Actual Study Start Date : March 1, 2017
Actual Primary Completion Date : February 6, 2018
Actual Study Completion Date : February 6, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: HFNC therapy
Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy will be implemented to CO-poisoned patients. Oxygen flow rate will be started 60 L/min and be decreased as the patient has requested.
Device: Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy

A high flow nasal cannula will be implemented to the CO-poisoned patients. In the meantime, intravenous access and cardiac monitorization will have been establishing. When the high flow nasal cannula becomes ready, the first venous blood sample will be taken and the treatment will be started without any delay. The gas flow rate will be started at the rate of 30 liters per minute and will be increased to the max flow rate which patient can tolerate and FiO2 of 1.0. If the first COHb level is lesser than 10%, the patient will be excluded and will receive standard emergency care.

The blood sample will be drawn from existing IV access every 10 minutes until the COHb levels become %50 or lesser of the initial level.

Once the COHb level becomes 50% of initial measurement, following blood samples will be taken in every 30 minutes.





Primary Outcome Measures :
  1. Half life of COHb [ Time Frame: between 20 and 120 minutes ]
    Half life of COHb levels (%) under the high flow nasal oxygen therapy. Elimination rate of COHb will be determined in every 10 minutes according to venous blood gas COHb level.


Secondary Outcome Measures :
  1. Adverse Events [ Time Frame: between 0 and 120 minutes ]
    Mucosal dryness, epistaxis and burn in the nasal cavity will be evaluated as a adverse events of high flow nasal cannula.

  2. Device Comfort [ Time Frame: Between 0 and 120 minutes ]
    Patient comfort will be assessed according to verbal numeric rating scale by asking to patient to say a number between 0 to 10 with 0 being "high flow nasal cannula can not be tolerated" and 10 being " the most comfortable breath ever".

  3. Flow Rate Tolerability [ Time Frame: Between 0 and 120 minutes ]
    Flow rate tolerability will be assessed according to patient request to change in flow rate.

  4. Flow Temperature Tolerability [ Time Frame: Between 0 and 120 minutes. ]
    Flow temperature tolerability will be assessed according to patient request to change in flow rate.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The patients who are admitted to the emergency department with CO poisoning with a CoHB level of >10%.
  • The patients who accept to participate in the study.

Exclusion Criteria:

  • The patients who are <18 years old.
  • The patients who need mechanical ventilation
  • The patients who are implemented oxygen more than 30 minutes before the ED admission
  • The patients who will be transferred to the hyperbaric oxygen center before the CoHB levels are decreased to the half.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03342209


Locations
Layout table for location information
Turkey
Kocaeli University Medical Faculty
Kocaeli, Izmit, Turkey, 41300
Sponsors and Collaborators
Kocaeli University
Investigators
Layout table for investigator information
Study Chair: Elif Yaka, Assoc. Prof. Kocaeli University
Principal Investigator: İbrahim U Özturan Kocaeli University
Layout table for additonal information
Responsible Party: Ibrahim Ulas Ozturan, Principle Investigator, MD, Kocaeli University
ClinicalTrials.gov Identifier: NCT03342209    
Other Study ID Numbers: KIA 2016/286
First Posted: November 14, 2017    Key Record Dates
Last Update Posted: April 10, 2018
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Ibrahim Ulas Ozturan, Kocaeli University:
carbon monoxide toxicity
high flow nasal cannula
emergency department
Additional relevant MeSH terms:
Layout table for MeSH terms
Poisoning
Carbon Monoxide Poisoning
Chemically-Induced Disorders
Gas Poisoning